## Minutes: Steering Board meeting, 19 August 2020

verified that all participants attending the	e meeting had signed the
declaration of confidentiality and absence of conflict of interest.	
1. Update on discussions with CureVac	
The Joint Negotiation Team concluded discussions with CureVa	oc
JNT presented details of each element of the agreement to the S	Steering Board and responded to
detailed questions. The agreement with CureVac includes a com-	unitment to buy doses (Article 4
of the Agreement between European Commission and MS)	), however,
This is unRNA vaccine  EU based manufacturing base and plans to supply first.	. The company has an
Steering Board Members congratulated the JNT team for reach company. The EC will send to CureVac shortly. A also publish a press release. Scientific presentation will be org submits However, the scientific advisers in Steering Board had already expressed a positive opinion on the v	As for other companies, EC will canised as soon as the company the session organised for the
informed all Steering Board members that  Furthermore, the	representative shared the
timeline for CureVac for different stages of clinical studies. Clini	ical stage 1 is now completed.
2. Update on discussions with Moderna	
The discussions are	ability.
3. Update on discussions with BioNTech	
The discussions are	agreed.
4. Update on discussions with Sanofi	

The evaluation process in ongoing. The team had a productive meeting on the drafting of the

## 5. Update on discussions with J&J

contract.

The deadline	for	submitting	the
--------------	-----	------------	-----

## 6. AZ contract

Member States were reminded of the 5 days op	t out period for the AZ contract, which for most		
of MS elapses on Friday 21 August. For	, who have national holidays, the		
deadline is on Monday 24 August, The EC will	distribute the pro rata allocation table based on		
Eurostat 2020 data,			
	doses. Member States agreed that the minimum ch close collaboration between neighbouring MS		
will be needed,			
7. Covax			
The EU continues to support the COVAX facility. The deadline for the Members States to react			
to the invitation of joining the facility is now postponed to 31st August.			
	More information will be		
provided at the upcoming Steering Board mee	ting. One of the outstanding issue stressed by		
several COVAX participants and currently discussed is			

The EU is also indirectly supporting the availability of the vaccines for the global community by giving money to vaccine producers for development and manufacturing vaccines via APAs. Once vaccines are developed, everyone will benefit from them.